Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Angle PLC

angleplc.com

Latest From Angle PLC

Angle Edges Closer To US FDA Clearance For Liquid Biopsy System

Angle is moving closer to becoming the first company to receive US FDA-clearance for a system that captures and harvests intact circulating tumor cells from patient blood for analysis.

Clinical Trials Research & Development

Market Intel: Liquid Biopsy – Ready For Prime Time?

Liquid biopsy is a rapidly developing noninvasive technology for the early detection of cancer. Multiple companies have entered clinical testing, using mostly blood to detect circulating tumor cells and/or circulating tumor DNA. But urine and even cerebral spinal fluid are promising liquids too. Regardless of the fluid, testing costs a fraction of a traditional, invasive tissue biopsy and offers much quicker results.

Commercial Innovation

Market Intel: Liquid Biopsy II – Emerging Companies Look For Liquid Gold

The potential to use a simple blood test to guide physicians in monitoring cancer therapies, detect early cancers, serve as a companion diagnostic to guide targeted therapeutics and predict the likely course or outcomes of disease in patients has spurred a lot of interest and innovation. Here's a look at emerging companies hoping to make an impact, including insights from interviews conducted with C-Level visitors at the recent Liquid Biopsy Conference in San Francisco. This is the second of a two-part series focusing on the global liquid biopsy market.

Cancer Personalized Medicine

FDA Pathway Options Are Growing For Diagnostics, FDA's Gottlieb Tells Commercial Labs

While lab-developed test (LDTs) remain under a US FDA enforcement discretion policy, the agency is working on several fronts to offer appealing regulatory pathways for advanced diagnostic services, FDA Commissioner Scott Gottlieb told American Clinical Laboratory Association members.

Legislation Regulation
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Angle PLC
  • Senior Management
  • Andrew Newland, CEO
    Ian Griffiths, CFO
    Jay Lewington, CTO
    Michael O'Brien, Dir., Bus. Dev.
  • Contact Info
  • Angle PLC
    Phone: 1483 343434
    10 Nugent Rd.
    Surrey Research
    Guildford, GU2 7AF
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register